Hirofumi Matsumoto

St. Marianna University School of Medicine — Japan

Medicine · Health Sciences

16h-index1.1kcitations132works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(24), Immunotherapy and Immune Responses(21), Spine and Intervertebral Disc Pathology(11), Lung Cancer Treatments and Mutations(9), Infectious Diseases and Tuberculosis(9)

Publications131 total

Ki‐67 evaluation using deep‐learning model‐assisted digital image analysis in breast cancer
Histopathology·2024· 6 cited
Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms
Pathology International·2024· 1 citedOpen Access
Utility of Combining Transcranial Sonography and MIBG Myocardial Scintigraphy to Evaluate Substantia Nigra in Patients with Parkinson’s Disease
Brain Sciences·2024· 1 citedOpen Access
The efficacy and safety of adaptive servo-ventilation therapy for heart failure with preserved ejection fraction
Heart and Vessels·2023· 2 cited
Unusual presentation of breast adenoid cystic carcinoma resembling adenomyoepithelioma with multiple distinct foci
Pathology - Research and Practice·2023· 1 cited
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Naoki Yoshimi(10), Takafumi Abo(6), Takeshi Nagayasu(6), Norihiro Nakada(6), Junichi Arai(5), Norie Abe(5), Mikiko Unesoko(5), Hisamitsu Zaha(5), Hiroshi Tsumura(4), Tomoshi Tsuchiya(4), H Aoyama(4), Atsushi Nanashima(4), Puay Hoon Tan(3), Mitsuhiro Takasita(3), Katsunori Takagi(3), Hiroaki Takeshita(3), Yuma Tsuruta(3), Masanao Saio(3), Yukiko Yano(3), Yasunori Fujioka(3)